Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have identified a promising solution to improving treatments offered to patients with cystic fibrosis.
This advancement, published in Frontiers in Cellular and Infection Microbiology, could lead to the development of new personalized therapies in the near future.
“Adding molecules called quorum-sensing inhibitors to current drugs not only reduces bacterial production of certain harmful residues but also restores the efficacy of existing treatments on the cells of cystic fibrosis patients,” explained Emmanuelle Brochiero, a researcher at the CRCHUM and a professor at Université de Montréal.
Cystic fibrosis is a fatal genetic disease affecting children and adults. It is characterized by excessive mucus production in several organs, recurrent bacterial infections and progressive lung damage. To date, no cure has been found. When the disease is too far advanced, the only option is to perform a lung transplantation.